First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

Posted on by

Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection OEGSTGEEST, Netherlands, Aug. 31, 2023 /PRNewswire/ — ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.